Truist Financial Upgrades Vericel (NASDAQ:VCEL) to "Buy"
Vericel (NASDAQ:VCEL – Get Free Report) was upgraded by equities researchers at Truist Financial from a “hold” rating to a “buy” rating in a research report issued on Thursday, Briefing.com reports. The firm presently has a $51.00 price objective on the biotechnology company’s stock, up from their prior price objective of $39.00. Truist Financial’s target […]